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Abstract 
This analysis aimed to examine the association between remission and quality of life 
(QOL) in schizophrenia. In post-hoc analyses of the 3-year, prospective, 
observational Schizophrenia Outpatients Health Outcomes (SOHO) study, we 
compared the QOL of patients who achieved symptomatic and clinical remission 
with those who did not, and the factors associated. Symptomatic remission was 
defined as achieving a score of ≤ 3 on the Clinical Global Impressions-
Schizophrenia (CGI-SCH) scale, maintained for at least 6 months and without 
hospitalization. QOL was patient self-rated using the European-QOL. Of the 6516 
patients analysed, 38% were in symptomatic remission 12 months post-baseline and 
52% at 36 months. Functional remission remained fairly constant from 12 months to 
36 months (22.4% at both time points). At all visits from 12 to 36 months, patient 
QOL and social functioning were significantly higher for patients in symptomatic 
remission. QOL was higher in patients in functional remission compared to those 
not in functional remission at all time points. Patients with maintained symptomatic 
remission over the 3-year follow-up had a much greater improvement in QOL than 
patients with no symptomatic remission or symptomatic remission for part of the 
period. Factors associated with a better QOL included symptomatic remission, paid 
employment, socially active, having a higher CGI-SCH cognitive score, good 
compliance, and a better baseline QOL. Achieving symptomatic remission in 
schizophrenia is associated with an increase in patient self-perceived QOL, even 
when adjusting for confounding factors. 
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1 Introduction 
A few years ago, the Remission in Schizophrenia Working Group (Andreasen et al., 
2005) proposed that treatment effects should be assessed using measures that have a 
significant meaning for the patient. Most clinical trials have used a clinical severity 
scale, such as the Positive and Negative Syndrome Scale (PANSS) or the Brief 
Psychiatric Rating Scale (BPRS), as the main outcome measure. However, a 
decrease in such scale scores cannot easily be translated into patient clinical status. 
The Working Group proposed ‘remission’ as a construct that has a clear meaning for 
patients and, thus, has direct implications for their well-being. Remission has been 
defined as having none or a minimal level of symptoms in key areas of 
schizophrenia for a period of 6 months or more (Andreasen et al., 2005).  
 
Since then, this definition of symptomatic remission has been applied in a number of 
studies with different samples of patients with schizophrenia in an attempt to 
validate it (Lasser et al., 2007; Boden et al., 2009; Ciudad et al., 2009). These 
validation studies applied an external validity criterion by comparing the key 
functioning and quality of life aspects of patients who were in symptomatic 
remission with those who were not in symptomatic remission. The findings of better 
social functioning for patients in symptomatic remission were highly consistent 
(Lasser et al., 2007), whereas the quality of life results were discordant (van Os et 
al., 2006; Emsley et al., 2007; Wunderink et al., 2007; Boden et al., 2009). Some 
studies found that patients in symptomatic remission did not have a better quality of 
life than patients not in symptomatic remission (van Os et al., 2006; Wunderink et 
al., 2007), while others found a difference in quality of life between remitters and 
non-remitters (Emsley et al., 2007; Boden et al., 2009). The differences may be 
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explained by the use of different measures of quality of life, and because some 
studies had small sample sizes.  
 
Quality of life is complex and influenced by many social, psychological and clinical 
factors, including the patient’s age and sex, insight into illness, severity of current 
symptoms, and side effects of medications (Hofer et al., 2004). Katschnig (2000) 
proposed that quality of life encompassed three areas; subjective 
wellbeing/satisfaction, and two objective aspects related to functioning and external 
resources. Among psychiatric patients, the relationship between these areas is 
complex, and the different areas have more or less influence on overall quality of 
life depending on the impact of disease at that point in time; when disease has a 
large impact on functioning, quality of life is reduced (Becker et al., 2005). A 
variety of measures are used to assess quality of life, including patient self-report 
measures (e.g. a summary measure on a visual analogue scale, VAS) and clinician-
rated scales (e.g. the Heinrich’s QOL). There is, however, a discrepancy between 
self-reported and clinician-rated quality of life, as many of the clinician-rated scales 
measure functioning rather than subjective well-being (Lazalvia et al., 2002; Jung et 
al., 2010). In this analysis, we were interested in self-reported quality of life as the 
impact of multiple relevant factors in a single, global, subjective judgement as a 
summary rating on a VAS. The setting of studies of quality of life is also important; 
quality of life measures have been applied in naturalistic settings and in clinical 
trials, but only the former setting characterizes the broader range of patients seen in 
everyday clinical practice. As quality of life profiles are reported by patients, not 
their clinicians, they are of interest to purchasers and providers of psychiatric 
services. 
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Some of the studies that found an association between quality of life and 
symptomatic remission did not take into account the presence of confounders 
(Boden et al., 2009): factors such as gender, age, or medication are known to be 
associated with both quality of life and symptomatic remission frequency, and may 
confound the relationship. van Os et al. (2006) did take confounding factors into 
account, but did not find an association between quality of life and symptomatic 
remission. In addition to these clinical factors, there are many other social factors 
that influence quality of life and may also confound the results. 
 
The Schizophrenia Outpatients Health Outcomes (SOHO) study, a 3-year 
prospective, observational study on the course of schizophrenia in the outpatient 
setting (conducted from September 2000 to January 2005), provides an excellent 
opportunity to address the issue of whether remission and quality of life are related. 
The objectives of these post-hoc analyses are to compare the quality of life of 
patients who achieve symptomatic remission of schizophrenia with those who do 
not achieve symptomatic remission. We also analyse whether the association 
between symptomatic remission and quality of life, if present, can be explained by 
the presence of confounding factors. For this, the regression model can be adjusted 
for other factors known to impact on quality of life and to be associated with 
remission (e.g. age, gender and medication) (Haro et al., 2006; Yen et al., 2008; 
Potkin et al., 2009). Finally, we have described the relationship between functional 
remission and quality of life. 
 
2 Methods 
6 
 
The SOHO study was a prospective, observational study conducted in 10 European 
countries. The rationale, design and methods of the study have been described in 
detail elsewhere (Haro et al. 2003b). Full ethical approval (including patient 
consent) was obtained in all countries, either at the site, region or national level, 
depending on country regulations. The study was carried out in accordance with the 
Declaration of Helsinki. A total of 1096 psychiatrists offered enrolment to patients 
who were: initiating or changing antipsychotic medication for the treatment of 
schizophrenia (diagnosed using ICD-10 or DSM-IV criteria); presenting within the 
normal course of care in the outpatient setting or in the hospital when admission was 
planned for the initiation or change of antipsychotic medication and discharge 
planned within 2 weeks; at least 18 years of age; and not participating in an 
intervention study. Patients were included irrespective of the reason for treatment 
change (e.g. lack of response, side effects, etc.), and regardless of whether an 
antipsychotic drug was being initiated as a replacement for a previous medication, 
was an addition to existing treatment, or was being initiated for the first time or after 
a period of no treatment. 
 
Since the initial objective of the SOHO study was to compare treatment with 
olanzapine versus treatment with other antipsychotics, the study was designed to 
provide two patient cohorts of approximately equal size: patients who initiated 
therapy with or changed to olanzapine; and patients who initiated therapy with or 
changed to a non-olanzapine antipsychotic. To achieve approximately equal 
numbers in the olanzapine and non-olanzapine groups, different sample fractions 
entered each cohort. This resulted in a stratified sample, with the olanzapine group 
as the ‘over-sampled’ stratum. In the present analyses, however, the non-olanzapine 
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group was divided into groups according to the specific antipsychotic medication 
prescribed.  
 
Effort was made to avoid interference with clinical practice. Investigators were 
instructed to make treatment decisions independently of the study and then evaluate 
whether patients were eligible for inclusion based on the entry criteria and the 
alternating structure of enrolment. The recruitment period was intentionally long 
and no minimum number of cases was required by each investigator.  
 
Patients were evaluated during visits occurring within the normal course of health 
care, which were planned at approximately 3, 6, 12, 18, 24, 30 and 36 months after 
baseline. The routine outpatient visit at which patients were enrolled served as the 
time for baseline data collection. 
 
Clinical severity was assessed using the Clinical Global Impression-Schizophrenia 
scale (CGI-SCH) (Haro et al., 2003c), which evaluated positive, negative, cognitive, 
depressive and overall symptoms in the week before the day of assessment. This 
physician-rated scale ranges from 1 (not ill) to 7 (among the most severely ill).  
 
Health-related quality of life (HRQL) was assessed using the European Quality of 
Life Questionnaire (EQ-5D, formerly EuroQol) (Brooks et al. 2003). This is a 
patient self-rated, generic, HRQL instrument that includes a visual analogue scale 
(EQ-VAS) which patients use to assess their perceived current level of health on the 
day of scoring from 0 (worst imaginable health state) to 100 (best imaginable health 
state).  
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Other data collected included socio-demographics, psychiatric history, patient 
functioning, medication use and adverse events. Data on baseline variables such as 
employment and social activities were collected using single-item questions 
completed by the participating investigators to the best of their knowledge including 
onformtion from the patient and other sources and assessing the status during the 
previous four weeks. 
 
Further details about the design of the SOHO study and the results at 6 months and 3 
years have been provided elsewhere (Haro et al., 2003a; 2003b; 2003c; Haro et al., 
2005; Haro et al., 2006).
 
 
 
2.1 Definition of remission 
In this analysis, remission was described in two ways; symptomatic remission 
(based on the CGI-SCH) and functional remission (based on social functioning). 
  
Symptomatic remission was defined as achieving a score of 3 (mild severity) or less 
on the 1–7 scale for each of the CGI-SCH items of overall severity, positive, 
negative and cognitive symptoms, and maintained for a period of 6 months or more. 
In addition, the patient must not have been hospitalized for their schizophrenia 
during this period. This definition has been shown to have an excellent agreement 
(Cohen’s kappa value of 0.80) with the Remission in Schizophrenia Working Group 
definition (Haro et al., 2007). In order to avoid a bias in favour of patients who 
entered the study with a good clinical status, symptomatic remission was defined 
starting at the 6-month visit. 
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Functional remission was based on good social functioning and was defined at each 
visit. To achieve functional remission required the patient to fulfill three criteria: i) 
positive occupational/vocational status (i.e. paid or unpaid full- or part-time 
employment, being an active student in university, or housewife); ii) living 
independently; iii) socially active (i.e. having more than one social contact during 
the last 4 weeks or having a spouse or partner). 
 
2.2 Statistical analysis 
Only patients assessed at all visits or having at most one missing visit were included 
in the analysis. For patients with one missing visit, values from the previous visit 
were imputed for that visit (n = 6752). Of these, 236 (3.5%) had missing 
information on CGI-SCH ratings and were not included in the analysis. Thus, a total 
of 6516 patients were included in the analysis. 
 
Baseline characteristics of the study sample were summarized using descriptive 
statistics. Quality of life (EQ-VAS) and functional remission (percentage of patients 
in a relationship, living independently, in paid employment, and socially active) at 
each visit from 12 months onwards were compared with patients in functional 
remission and not in remission at that visit using Student’s t-tests and χ2 tests. 
 
Based on the above definition of symptomatic remission, patients were also 
classified into one of three symptomatic remission groups based on their 
symptomatic remission status over the whole 3-year follow-up period: 
i) Those not achieving symptomatic remission at any time during follow-up 
(no symptomatic remission); 
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ii) Those starting symptomatic remission at 6 months and maintaining 
symptomatic remission during the 3 years (always symptomatic 
remission); 
iii) Patients achieving symptomatic remission only for part but not all of the 
6-month periods during the 3-year follow-up period (some symptomatic 
remission). 
 
Patients were classified into the following treatment groups: olanzapine, risperidone, 
quetiapine, amisulpride, clozapine, oral typical antipsychotics, depot typical 
antipsychotics and combination therapy. Patients taking any other atypical 
antipsychotics at baseline were excluded from the analysis because of the small 
number of patients in those groups.  
 
To analyse factors associated with quality of life, a generalized estimating equation 
(GEE) linear regression model was fitted with EQ-VAS as the dependent variable, 
including all observations from 6 months onwards. An observation was included in 
the model for each visit of each patient. An auto-regressive correlation structure 
(AR(1)) matrix was defined. The covariates in the model were chosen based on a 
backward reduction method. The initial list of covariates were country, gender, 
never treated before SOHO, age at first treatment contact, time since first treatment 
for schizophrenia, current alcohol abuse or dependence, current substance abuse or 
dependence, suicide attempts in past 6 months, CGI-SCH overall score, CGI-SCH 
positive score, CGI-SCH negative score, CGI-SCH cognitive score, CGI-SCH 
depressive score, hostility/aggression in past 6 months, compliance, body mass 
index, relationship with spouse or partner, living independently, work status 
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(employed and paid versus not), social activities in past 4 weeks, anticholinergic, 
antidepressant, anxiolytics/hypnotics and mood stabilizer concomitant medication, 
EQ-VAS score at baseline. As patients could change medication at any point during 
the study, the medication that was included in each observational period as a 
dependent variable was the medication the patient was taking upon presentation to 
that visit. The final model was repeated including only those patients who 
maintained the same antipsychotic medication throughout the 3-year follow-up 
period. 
 
All statistical analyses were performed with SAS version 9.1 (SAS Institute, Inc., 
Cary, NC, USA). 
 
3 Results 
A total of 6516 (63.8%) patients were included in the analysis, and 3702 (36.2%) 
were excluded; there were no relevant differences between the patients included and 
excluded from the analysis. For example, mean overall symptom scores for included 
patients were 4.4 (SD 1.0) and for excluded patients were 4.5 (SD 1.0) and mean 
EQ-VAS scores for included patients were 46.3 (SD 21.0) and for excluded patients 
were 46.1 (SD 21.7). A total of 24 patients (0.2%) of patients were excluded from 
the analysis because they took other atypical antipsychotics at baseline. 
 
The characteristics of the included population at baseline are summarized in Table 
1. Of these patients, 3984 (61.1%) maintained their baseline medication at 36 
months. The mean age of the sample was 40.2 years and 57.6% were men. Patients 
had a long duration of illness (mean 11.8 years) and moderate-to-severe symptoms 
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(CGI-SCH overall mean 4.4). Patient social functioning at baseline was as follows: 
29.4% were in a relationship (spouse or partner), 47% lived independently, 19.6% 
were in paid employment, and 68.2% were socially active. The patients’ quality of 
life at baseline was a mean EQ-VAS rating of 46.3 (SD 21.0). 
 
Of the 6516 patients analysed, 38% of patients were in symptomatic remission at the 
12-month post-baseline visit. The percentage of patients in symptomatic remission 
had increased to 45% at the 18-month visit and to 52% at the 36-month visit. Patient 
quality of life and social functioning by symptomatic remission status at each 
follow-up visit from 12 months to 36 months are presented in Table 2 and Fig. 1, 
respectively. Patients in symptomatic remission had a significantly higher EQ-VAS 
score at all visits compared with patients not in symptomatic remission (P < 0.001). 
Likewise, at all visits, a significantly higher percentage of patients in symptomatic 
remission were in a relationship, living independently, in paid employment and 
socially active compared with patients not in symptomatic remission (P < 0.001). 
 
When the patients were classified according their symptomatic remission status over 
the 3-year follow-up period, 35% had no symptomatic remission, 38% had always 
symptomatic remission, and 26% had some symptomatic remission. All three patient 
groups experienced improvements in their quality of life during follow-up, but the 
improvement was much greater in the always symptomatic remission group 
compared with the other two groups. Mean EQ-VAS in the always symptomatic 
remission group was 48.5 (SD 20.2) at baseline and 79.3 (SD 14.2) at 36 months. In 
the never symptomatic remission group, the corresponding mean EQ-VAS scores 
were 44.9 (SD 21.4) and 60.5 (SD 19.1), respectively. Finally, in the group of 
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patients experiencing some remission, mean EQ-VAS ratings were 46.0 (SD 21.0) at 
baseline and 72.1 (SD 16.5) at 36 months. At each of the time points, differences 
between the three patient groups were statistically significant. 
 
The percentage of patients in functional remission remained constant over time; the 
number of patients in functional remission was 1439 (22.4%) at 12 months, 1426 
(22.2%) at 18 months, 1407 (22.0%) at 24 months, 1421 (22.2%) at 30 months, and 
1368 (22.4%) at 36 months. EQ-VAS scores at each visit were compared for 
patients achieving functional remission with patients not achieving functional 
remission. At 12 months, mean EQ-VAS scores were 69.0 (SD 18.4) for those 
achieving functional remission versus 63.4 (SD 19.1) for those not achieving 
remission (table 2). At 18 months these scores were 71.7 (SD 17.9) versus 65.0 (SD 
19.2); at 24 months these scores were 72.6 (SD 17.9) versus 66.4 (SD 18.3); at 30 
months these scores were 74.3 (SD 17.7) versus 67.0 (SD 18.5); and at 36 months 
these scores were 76.0 (SD 17.2) versus 68.5 (SD 18.4), for those achieving 
functional remission versus those not achieving remission, respectively. There were 
significant differences between these scores at all time points (P<0.0001). 
 
Factors independently associated with quality of life (EQ-VAS) during the 3-year 
follow-up period are summarized in Table 3. The value of the estimate in Table 3 
represents the estimated difference in EQ-VAS ratings for patients in that category. 
As higher EQ-VAS values represent better quality of life, when the estimate is 
positive, that factor is associated with better quality of life. Being in symptomatic 
remission was strongly associated with a better quality of life as perceived by 
patients using the EQ-VAS. Other factors associated with a better quality of life 
14 
 
were being in paid employment, being socially active, having a higher CGI-SCH 
cognitive score, a better quality of life at baseline, and compliance. Compared to 
patients who were not compliant at baseline, patients who were always compliant or 
partially compliant had a better quality of life at followup. Also patients who were 
not taking medication at baseline (some patients had never received antipsychotic 
treatment before baseline) had better quality of life outcomes. In contrast, factors 
associated with a worse quality of life were: male gender, older age at first 
treatment, longer duration of illness, higher CGI-SCH negative and depressive 
symptom scores at baseline, being prescribed anxiolytics or mood stabilizers, and 
treatment with amisulpride, typical antipsychotics (depot, oral), quetiapine, 
risperidone or combination therapy versus olanzapine (Table 3). 
  
Similar results were obtained when the analysis included only those patients who 
maintained the antipsychotic treatment prescribed at baseline during the 3 year 
follow-up (data not shown but available on request). 
 
4 Discussion 
The objective of treatment in schizophrenia must be to improve patient quality of 
life. Our results show that achieving symptomatic remission in schizophrenia is 
associated with an improvement in patient self-perceived health-related quality of 
life, even when confounding factors are taken into account. Furthermore, because 
SOHO was an observational study in outpatients with schizophrenia, our results not 
only provide support for the external validity of the symptomatic remission 
construct, but also the usefulness of measuring symptomatic remission in everyday 
clinical practice, especially in patients requiring a change of antipsychotic treatment. 
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The findings of this analysis should be considered in the context of patient self-
reported quality of life (as specifically assessed using the EQ-5D, Brooks et al., 
2003), rather than clinician-reported quality of life, which as discussed previously, 
tend to measure functioning rather than subjective quality of life (Lazalvia et al., 
2002; Jung et al., 2010). 
 
Previous studies examining the relationship between symptomatic remission and 
quality of life showed inconsistent results (van Os et al. 2006; Emsley et al. 2007; 
Wunderink et al., 2007; Boden et al., 2009). Our study goes beyond previous 
studies, which were limited by small sample sizes or did not adjust for confounding. 
In addition, most previous studies were cross-sectional in design or based on the 
highly controlled clinical circumstances of randomized clinical trials. In contrast, 
SOHO was a large, naturalistic, prospective study in the outpatient setting, which 
increases the generalizability of the findings. Moreover, our analyses controlled for 
the presence of other important factors that frequently affect quality of life and 
symptomatic remission, such as age, duration of illness, antipsychotic treatment, 
social activity and employment status. 
 
In the present study, 52% of patients were in symptomatic remission at the 36-
month visit. Similar percentages of patients achieved symptomatic remission in the 
3-year extension study of a controlled clinical trial, where symptomatic remission 
rates ranged from 41% in haloperidol-treated patients to 50% in ziprasidone-treated 
patients (Potkin et al., 2009). 
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Symptomatic remission status, however, can change over time, and so can patient 
quality of life. We have shown that patients who achieve symptomatic remission 
continue to experience improvements in their quality of life over time if 
symptomatic remission is maintained. This indicates that quality of life continues to 
improve when symptomatic symptomatic remission is maintained and this is 
consistent with previous research (Dunayevich et al., 2006). This finding, together 
with the need for good compliance with medication, signals the relevance of 
maintenance treatment in schizophrenia. 
 
Patients in symptomatic remission reported having a better quality of life compared 
with patients not in remission. The mean EQ-VAS score at 3 years for remitters was 
similar to that reported for the general population (König et al., 2009). Previous 
reports have found that quality of life in patients with schizophrenia in symptomatic 
remission is lower than in healthy individuals (Yen et al., 2008). However, the study 
by Yen et al. (2008) did not use a representative sample of general population 
subjects and did not specify for how long the patients included had been in 
remission. 
 
In agreement with other studies (van Os et al., 2006; Lasser et al., 2007; Ciudad et 
al., 2009), we found that patients who achieved symptomatic remission had better 
social functioning (as measured with the frequency of having paid employment, 
living independently, being in a relationship, and being socially active) than patients 
not achieving symptomatic remission.
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There is an emphasis on psychosocial functioning after clinical remission as the 
most important outcome in schizophrenia. Quality of life has usually been given less 
attention, but it should be of great relevance for the well-being of the patient 
(Cardoso et al., 2006; Juckel et al., 2008). Although related, clinical remission, 
social functioning and quality of life are different entities that depend on different 
factors (Lambert et al., 2006).  
 
The proportion of patients in functional remission was much lower than those in 
symptomatic remission. Besides, the proportion of patients in symptomatic 
remission increased during follow-up, while the proportion of patients in functional 
remission presented a much more stable course. This highlights the difficulty of 
improving patient functioning when disability has been established. 
 
Gender is a potential confounding factor in the association between symptomatic 
remission and quality of life. In a previous report of the 3-year results of the SOHO 
study, men with schizophrenia were less likely to achieve symptomatic remission 
than women (Haro et al., 2006). Moreover, in the present analysis, we found that 
men had a slightly worse quality of life (EQ-VAS) than women. In contrast, in the 
general population, women report a lower HRQL than men (Gallicchio et al., 2007). 
Moreover, previous studies in schizophrenia have shown inconsistent results. 
Women with serious mental health problems (including schizophrenia) reported 
poorer HRQL than men across several domains of the Short Form (36) Health 
Survey (SF-36), but reported better self-perceived health (Teh et al., 2008). In a 
cross-sectional study using the Quality of Life scale, women with schizophrenia had 
better quality of life scores than men (Cardoso et al., 2006). Further studies 
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exploring the effect of gender on symptomatic remission and HRQL in 
schizophrenia are needed. 
 
Longer duration of illness was associated with a lower quality of life during follow-
up. There may be two explanations for this. Firstly, quality of life decreases with 
age. Secondly, quality of life decreases with a chronic course of illness; that is, 
patients who continue experiencing symptoms at older ages have a more disabling 
illness. 
 
In the present study, patients with more severe depressive or negative symptoms had 
a lower quality of life. This is consistent with previous studies (Yamauchi et al., 
2008). These symptoms are more important than positive symptoms in explaining 
patients’ quality of life during the maintenance treatment of schizophrenia. They are 
also associated with higher costs (Knapp et al., 2008).  
 
Patients with a higher level of cognitive symptoms reported a somewhat better 
quality of life. This finding must take into account that self-evaluation of quality of 
life by patients with cognitive impairment may be more problematic. Higher 
cognitive impairment has been associated with a lower quality of life in patients 
with bipolar disorder (Brissos et al., 2008), but the results are not consistent for 
schizophrenia (Patel et al., 2006). Moreover, Brissos et al. (Brissos et al., 2008) did 
not adjust for the presence of symptoms. 
 
Compliance has a favourable effect on patient quality of life. We found that patients 
who were compliant with their antipsychotic medication had a better quality of life 
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(EQ-VAS). Furthermore, patients treated with olanzapine showed a better quality of 
life than patients treated with oral or depot typical antipsychotics, quetiapine, 
amisulpride and risperidone. This is in accordance with previous studies (Silva de 
Lima et al., 2005), and is consistent with the 6- and 36-month results from the 
SOHO study (Haro et al., 2007; Alonso et al., 2009).  
 
Several limitations must be considered when analysing these results. Firstly, our 
definition of symptomatic remission was based on the CGI-SCH scale, and not on 
the scales initially recommended by the Remission in Schizophrenia Working Group 
(Andreasen et al., 2005). Nevertheless, the definition used in this analysis has shown 
high agreement with the Consensus Group Definition (Haro et al., 2007). Secondly, 
patients enrolled in the SOHO study were not representative of all patients with 
schizophrenia, but of patients changing treatment in the outpatient setting. However, 
the socio-demographic characteristics of the patients included in the SOHO study 
are similar to those in studies including prevalence samples of patients with 
schizophrenia. Finally, SOHO is an international study and we have not analysed 
country differences in the relationship. 
 
In conclusion, this study in the real-life clinical practice setting provides further 
evidence of an association between remission and quality of life. Patients who 
achieved remission had better self-rated social functioning and quality of life than 
patients not meeting the remission criteria. Moreover, the association between 
quality of life and remission persisted even when confounding factors were taken 
into account. 
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Fig. 1. 
Social functioning by remission status at each follow-up visit. 
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Table 1 
Demographic and clinical characteristics of the study sample at baseline (n = 6516). 
Parameter Mean (SD) or number (%) 
Gender (% male) 3729 (57.6) 
Age (years) 40.20 (12.9) 
Age at first contact (years) 28.46 (10.2) 
Duration of illness (years) 11.78 (11.0) 
Body mass index (kg/m
2
) 26.25 (4.8) 
CGI-SCH overall severity score 4.40 (1.0) 
CGI-SCH positive symptom score 3.80 (1.4) 
CGI-SCH negative symptom score 4.08 (1.3) 
CGI-SCH cognitive symptom score 3.76 (1.3) 
CGI-SCH depressive symptom score 3.44 (1.3) 
EQ-VAS 46.3 (21.0) 
Alcohol abuse at baseline (%) 165 (2.5) 
Substance abuse at baseline (%) 141 (2.2) 
Suicide attempts in six months before baseline (%) 264 (4.3) 
Relationship (spouse or partner) (%) 1857 (29.4) 
Living independently (%) 3058 (47.0) 
Being in paid employment (%) 1267 (19.6) 
Being socially active (%) 4390 (68.2) 
Compliance at baseline (%)  
Not prescribed antipsychotic 1327 (20.4) 
Always complies to antipsychotic 3986 (61.4) 
Half complies to antipsychotic 879 (13.5) 
Never complies to antipsychotic 304 (4.7) 
Treatment initiated at baseline (%)  
Olanzapine 3408 (52.3) 
Risperidone 1266 (19.4) 
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Quetiapine 486 (7.5) 
Amisulpride 192 (2.9) 
Clozapine 226 (3.5) 
Oral typical 444 (6.8) 
Depot typical 333 (5.1) 
2+ antipsychotics 161 (2.5) 
Anticholinergics prescribed at baseline (%) 1219 (18.7) 
Antidepressants prescribed at baseline (%)  1165 (17.9) 
Anxiolytics/hypnotics prescribed at baseline (%) 2384 (36.6) 
Mood stabilizer prescribed at baseline (%) 611 (9.4) 
CGI-SCH, Clinical Global Impression-Schizophrenia scale (range 1–7); EQ-VAS, European Quality of 
Life Questionnaire-Visual Analogue Scale 
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Table 2 
Quality of life (EQ-VAS) by symptomatic and functional remission status at each follow-up visit. 
 
Visit Symptomatic remission No symptomatic remission Functional remission No functional  remission 
 Mean (SD) Median Mean (SD) Median Mean (SD) Median Mean (SD) Median 
12 months 73.9 (15.1) 75 58.7 (19.0) 60 69.0 (18.4) 70 63.4 (19.1) 65 
18 months 75.2 (14.8) 76 59.3 (19.3) 60 71.7 (17.9) 75 65.0 (19.2) 67 
24 months 75.7 (14.5) 78 60.2 (18.6) 60 72.6 (17.9) 75 66.4 (18.3) 70 
30 months 76.6 (14.7) 79 60.3 (18.6) 60 74.3 (17.7) 77 67.0 (18.5) 70 
36 months 77.3 (14.6) 80 61.4 (18.8) 63 76.0 (17.2) 80 68.5 (18.4) 70 
All P < 0.001 for remission versus no remission 
EQ-VAS, European Quality of Life Questionnaire-Visual Analogue Scale 
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Table 3 
Factors associated with quality of life as measured with the EQ-VAS
*
. 
Variable (reference category) Estimate 95% CI P value 
In remission (versus not in remission) 5.903 237.288, 564.508 < 0.0001 
Male (versus female) –0.876 0.205, 0.846 0.0155 
Age at first treatment (per year) –0.069 0.898, 0.969 0.0003 
Duration of illness (per year) –0.140 0.839, 0.900 < 0.0001 
CGI-SCH negative score at baseline –0.346 0.501, 1.000 0.0500 
CGI-SCH cognitive score at baseline 0.622 1.358, 2.557 0.0001 
CGI-SCH depressive score at baseline –0.848 0.306, 0.599 < 0.0001 
In paid employment at baseline (versus not in paid 
employment) 
2.874 7.320, 42.805 < 0.0001 
Socially active at baseline (versus not socially active) 1.869 2.945, 14.262 < 0.0001 
Compliance with antipsychotic treatment at baseline 
(versus never complies) 
   
Always complies 2.724 2.525, 91.944 0.0030 
Complies half the time 2.352 1.487, 74.273 0.0184 
Not prescribed 3.252 3.826, 174.409 0.0008 
Body mass index –0.058 0.874, 1.019 0.1412 
Treatment (versus olanzapine)    
Amisulpride –1.919 0.028, 0.771 0.0234 
Clozapine –1.158 0.067, 1.477 0.1425 
Depot typical –3.978 0.005, 0.071 < 0.0001 
None –0.741 0.101, 2.239 0.3479 
Other atypical –0.035 0.069, 13.555 0.9792 
Oral typical –4.837 0.002, 0.029 < 0.0001 
Quetiapine –2.721 0.017, 0.251 < 0.0001 
Risperidone –1.921 0.060, 0.359 < 0.0001 
2+ antipsychotics –3.663 0.011, 0.058 < 0.0001 
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Prescribed anxiolytics at baseline (versus no 
anxiolytics) 
–1.181 0.145, 0.648 0.0020 
Prescribed mood stabilizers at baseline (versus no 
mood stabilizers) 
–1.336 0.078, 0.881 0.0303 
Baseline EQ-VAS 0.284 1.303, 1.356 < 0.0001 
*
GEE model including all visits after 6 months; the model is also adjusted for visit and country 
EQ-VAS, European Quality of Life Questionnaire-Visual Analogue Scale; CGI-SCH, Clinical Global 
Impressions-Schizophrenia scale 
Variables not included in the model for lack of significance were: never treated before SOHO, current 
alcohol abuse or dependence, current substance abuse or dependence, suicide attempts in past 6 months, 
CGI-SCH overall score, CGI-SCH positive score, hostility/aggression in past 6 months, relationship with 
spouse or partner, living independently, antidepressant, concomitant medication. 
 
 
